Literature DB >> 9682150

Determination of losartan and its degradates in COZAAR tablets by reversed-phase high-performance thin-layer chromatography.

K E McCarthy1, Q Wang, E W Tsai, R E Gilbert, D P Ip, M A Brooks.   

Abstract

Losartan potassium is an angiotensin II receptor blocker. It has been formulated and marketed as a tablet dosage from (COZAAR). A reversed-phase high-performance thin-layer chromatography method has been validated and shown to be sensitive, efficient, and reliable, and can be used as an excellent alternative to the HPLC stability testing of losartan potassium in COZAAR tablets.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9682150     DOI： 10.1016/s0731-7085(97)00251-3

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN： 0731-7085            Impact factor:   3.935


  5 in total

1.  Tautomerism in drug discovery.

Authors:  Alan R Katritzky; C Dennis Hall; Bahaa El-Dien M El-Gendy; Bogdan Draghici
Journal:  J Comput Aided Mol Des       Date:  2010-05-20       Impact factor: 3.686

2.  RP-HPLC Method for the Determination of Losartan Potassium and Ramipril in Combined Dosage Form.

Authors:  K Srinivasa Rao; K Srinivas
Journal:  Indian J Pharm Sci       Date:  2010-01       Impact factor: 0.975

3.  Spectrofluorimetric method for determination of some angiotensin II receptor antagonists.

Authors:  Salwa R El-Shaboury; Samiha A Hussein; Niveen A Mohamed; Mohamed M El-Sutohy
Journal:  J Pharm Anal       Date:  2011-11-10

4.  Stability-indicating Reversed-phase Liquid Chromatographic Method for Simultaneous Determination of Losartan Potassium and Ramipril in Tablets.

Authors:  S Kollipara; G Bende; Y Bansal; R Saha
Journal:  Indian J Pharm Sci       Date:  2012-05       Impact factor: 0.975

5.  Quantitative Determination of three Angiotensin-II-receptor Antagonists in Presence of Hydrochlorothiazide by RP-HPLC in their Tablet Preparations.

Authors:  Hany Mohammed Hafez; Abdullah Ahmed Elshanawane; Lobna Mohammed Abdelaziz; Magda Mohammed Kamal
Journal:  Iran J Pharm Res       Date:  2013       Impact factor: 1.696
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.